Back to top

Analyst Blog

Takeda Pharmaceutical (TKPYY) recently announced the launch of three type II diabetes drugs in the US - Nesina (alogliptin), Kazano (alogliptin and metformin hydrochloride), and Oseni (alogliptin and pioglitazone).

Nesina, Kazano and Oseni received US Food and Drug Administration (FDA) approval in Jan 2013. These drugs are to be used along with diet and exercise.

As per the FDA, type II diabetes affects roughly 24 million people, forming 90% of total diabetes patients in the US. The type II diabetes market is currently crowded with drugs like Januvia, Bydureon. Janumet, VIctoza and IDegLira

The FDA had asked for 5 post-marketing studies for Nesina, 2 for Kazano and 1 for Oseni. Kazano carries a boxed warning for lactic acidosis while Oseni carries a boxed warning for heart failure associated with pioglitazone use.

Nesina was launched in Japan in the year 2010. These three drugs are under review in the EU, where it was submitted in the second quarter of 2012. Takeda expects EU decision in the second half of 2013. 

In 2005, Takeda acquired development and marketing rights to all dipeptidyl peptidase IV (DPP4) inhibitors from Furiex Pharmaceuticals, Inc. .

The 2013 financial guidance provided by Takeda in May 2013 includes the effect of this launch. For 2013, Takeda expects Net sales of 1590 billion yen and earnings per share of 120.34 yen.

Takeda carries a Zacks Rank #3 (Hold). Other companies like Jazz Pharmaceuticals plc (JAZZ - Analyst Report) and Salix Pharmaceuticals Ltd. (SLXP - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%